We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Antibody Treatment Slows Lung Cancer Growth in Mouse Model

By LabMedica International staff writers
Posted on 17 Mar 2014
A monoclonal antibody that specifically binds to the surface marker ProAVP (pro-vasopressin) impaired the growth of small-cell lung cancer tumors in a mouse model.

Investigators at Dartmouth College (Hanover, NH, USA) previously had demonstrated that human small-cell lung cancer (SCLC) seemed to universally express the vasopressin gene, and this led to the presence of a cell surface marker representing the entire pro-hormone precursor.

Vasopressin, which is derived from a pro-hormone precursor that is synthesized in the hypothalamus and stored in vesicles at the posterior pituitary, is a peptide hormone that controls the reabsorption of molecules in the tubules of the kidneys by affecting the tissue's permeability. More...
It also increases peripheral vascular resistance, which in turn increases arterial blood pressure. It plays a key role in homeostasis, by the regulation of water, glucose, and salts in the blood.

The investigators treated a group of SCLC mice with MAG-1, a mouse monoclonal antibody specific for the pro-vasopressin C-terminal moiety. They reported in the February 14, 2014, online edition of the journal Frontiers in Oncology that the antibody attached to SCLC cells and it was internalized. Antibody treatment decreased the rate of increase in tumor size by half, and doubling time by about three-fold. Normal tissues seemed not to be affected.

"We are developing methods of antibody-targeted treatment for recurrent small-cell lung cancer," said senior author Dr. William G. North, professor of physiology at Dartmouth College. "Targeting with a humanized MAG-1 can likely be effective, especially when given in combination with chemotherapy, for treating a deadly disease for which there is no effective therapy."

Related Links:

Dartmouth College



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.